{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T16:57:18Z","timestamp":1795021038655,"version":"4.10.1"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.vaccine.2024.126663","type":"journal-article","created":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T20:08:03Z","timestamp":1735070883000},"page":"126663","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Design and evaluation of a multi-epitope HIV-1 vaccine based on human parvovirus virus-like particles"],"prefix":"10.1016","volume":"45","author":[{"given":"David","family":"P\u00e9rez-Saucedo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy Vanessa","family":"Castro-Perea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Ru\u00edz-Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismael","family":"Bustos-Jaimes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nica","family":"Viveros-Rogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonor","family":"Huerta-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leticia","family":"Moreno-Fierros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"35","key":"10.1016\/j.vaccine.2024.126663_bb0005","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1016\/j.vaccine.2013.05.018","article-title":"A brief history of the global effort to develop a preventive HIV vaccine","volume":"31","author":"Esparza","year":"2013","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2024.126663_bb0010","first-page":"119","volume":"7","author":"Wilmschen","year":"2019","journal-title":"Viral Vectors for the Induction of Broadly Neutralizing Antibodies against HIV"},{"issue":"2","key":"10.1016\/j.vaccine.2024.126663_bb0015","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s11904-019-00432-x","article-title":"The Antibodiome\u2014mapping the humoral immune response to HIV","volume":"16","author":"Butler","year":"2019","journal-title":"Curr HIV\/AIDS Rep"},{"key":"10.1016\/j.vaccine.2024.126663_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2021.101470","article-title":"HIV vaccinology: 2021 update","volume":"51","author":"Lee","year":"2021","journal-title":"Semin Immunol"},{"issue":"10143","key":"10.1016\/j.vaccine.2024.126663_bb0025","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0140-6736(18)31364-3","article-title":"Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1\/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)","volume":"392","author":"Barouch","year":"2018","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.vaccine.2024.126663_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2019.103791","article-title":"Exploring T & B-cell epitopes and designing multi-epitope subunit vaccine targeting integration step of HIV-1 lifecycle using immunoinformatics approach","volume":"137","author":"Abdulla","year":"2019","journal-title":"Microb Pathog"},{"issue":"2","key":"10.1016\/j.vaccine.2024.126663_bb0035","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.vaccine.2008.10.051","article-title":"Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial","volume":"27","author":"Spearman","year":"2009","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2024.126663_bb0040","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/s41591-018-0042-6","article-title":"Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1","volume":"24","author":"Xu","year":"2018","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.vaccine.2024.126663_bb0045","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1007\/s12033-015-9856-3","article-title":"A plant-derived multi-HIV antigen induces broad immune responses in orally immunized mice","volume":"57","author":"Rubio-Infante","year":"2015","journal-title":"Mol Biotechnol"},{"issue":"4","key":"10.1016\/j.vaccine.2024.126663_bb0050","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s00425-013-1932-y","article-title":"Immunogenic properties of a lettuce-derived C4(V3)6 multiepitopic HIV protein","volume":"238","author":"Govea-Alonso","year":"2013","journal-title":"Planta"},{"issue":"8","key":"10.1016\/j.vaccine.2024.126663_bb0055","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1080\/21645515.2016.1160977","article-title":"The promise and challenge of epitope-focused vaccines","volume":"12","author":"Oscherwitz","year":"2016","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"10.1016\/j.vaccine.2024.126663_bb0060","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/imr.12483","article-title":"Germline-targeting immunogens","volume":"275","author":"Stamatatos","year":"2017","journal-title":"Immunol Rev"},{"key":"10.1016\/j.vaccine.2024.126663_bb0065","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jbiotec.2019.10.004","article-title":"Adaptive laboratory evolution of stable insect cell lines for improved HIV-gag VLPs production","volume":"307","author":"Fernandes","year":"2020","journal-title":"J Biotechnol"},{"key":"10.1016\/j.vaccine.2024.126663_bb0070","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.virusres.2016.08.007","article-title":"Peptide presentation on primate erythroparvovirus 1 virus-like particles: in vitro assembly, stability and immunological properties","volume":"224","author":"del Carmen Mor\u00e1n-Garc\u00eda","year":"2016","journal-title":"Virus Res"},{"key":"10.1016\/j.vaccine.2024.126663_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virusres.2018.06.014","article-title":"Decoration of virus-like particles with an enzymatic activity of biomedical interest","volume":"255","author":"Cayetano-Cruz","year":"2018","journal-title":"Virus Res"},{"key":"10.1016\/j.vaccine.2024.126663_bb0080","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.imlet.2021.09.002","article-title":"B19-VLPs as an effective delivery system for tumour antigens to induce humoral and cellular immune responses against triple negative breast cancer","volume":"239","author":"Jim\u00e9nez-Ch\u00e1vez","year":"2021","journal-title":"Immunol Lett"},{"issue":"1","key":"10.1016\/j.vaccine.2024.126663_bb0085","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0022-1759(98)00170-7","article-title":"A statistically defined endpoint titer determination method for immunoassays","volume":"221","author":"Frey","year":"1998","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.vaccine.2024.126663_bb0090","series-title":"The ELISA guidebook","first-page":"149","article-title":"Practical Exercises","author":"Crowther","year":"2009"},{"issue":"1","key":"10.1016\/j.vaccine.2024.126663_bb0095","doi-asserted-by":"crossref","first-page":"14313","DOI":"10.1038\/s41598-020-71184-7","article-title":"The influence of proline isomerization on potency and stability of anti-HIV antibody 10E8","volume":"10","author":"Guttman","year":"2020","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.vaccine.2024.126663_bb0100","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/COH.0000000000000600","article-title":"Broadly neutralizing antibodies for the treatment and prevention of HIV infection","volume":"15","author":"Caskey","year":"2020","journal-title":"Curr Opin HIV AIDS"},{"issue":"3","key":"10.1016\/j.vaccine.2024.126663_bb0105","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1021\/ma00145a039","article-title":"Estimation of effective interresidue contact energies from protein crystal structures: quasi-chemical approximation","volume":"18","author":"Miyazawa","year":"1985","journal-title":"Macromolecules"},{"key":"10.1016\/j.vaccine.2024.126663_bb0110","series-title":"Comparison of hydrophobicity scales for predicting biophysical properties of antibodies","first-page":"9","author":"Waibl","year":"2022"},{"key":"10.1016\/j.vaccine.2024.126663_bb0115","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1477-3155-4-13","article-title":"Truncated forms of viral VP2 proteins fused to EGFP assemble into fluorescent parvovirus-like particles","volume":"4","author":"Gilbert","year":"2006","journal-title":"J Nanobiotechnol"},{"issue":"1","key":"10.1016\/j.vaccine.2024.126663_bb0120","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/imr.12506","article-title":"HIV antibodies for treatment of HIV infection","volume":"275","author":"Margolis","year":"2017","journal-title":"Immunol Rev"},{"key":"10.1016\/j.vaccine.2024.126663_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2020.101428","article-title":"Antibody-guided structure-based vaccines","volume":"50","author":"Kwong","year":"2020","journal-title":"Semin Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2024.126663_bb0130","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1080\/21645515.2015.1012017","article-title":"In silico design of a DNA-based HIV-1 multi-epitope vaccine for Chinese populations","volume":"11","author":"Yang","year":"2015","journal-title":"Hum Vaccin Immunother"},{"issue":"7","key":"10.1016\/j.vaccine.2024.126663_bb0135","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.4049\/jimmunol.1600817","article-title":"The lymphatic immune response induced by the adjuvant AS01: a comparison of intramuscular and subcutaneous immunization routes","volume":"197","author":"Neeland","year":"2016","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2024.126663_bb0140","series-title":"Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design","author":"Burton","year":"2016"},{"issue":"3","key":"10.1016\/j.vaccine.2024.126663_bb0145","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0166-3542(99)00032-7","article-title":"Lipoproteins account for part of the broad non-specific antiviral activity of human serum","volume":"42","author":"Singh","year":"1999","journal-title":"Antivir Res"},{"issue":"5447","key":"10.1016\/j.vaccine.2024.126663_bb0150","first-page":"2156","volume":"286","author":"Ochsenbein","year":"1999","journal-title":"Control of Early Viral and Bacterial Distribution and Disease by Natural Antibodies"},{"issue":"8","key":"10.1016\/j.vaccine.2024.126663_bb0155","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S0301-472X(01)00678-6","article-title":"Circulating natural IgM antibodies and their corresponding human cord blood cell\u2013derived Mabs specifically combat the tat protein of HIV","volume":"29","author":"Rodman","year":"2001","journal-title":"Exp Hematol"},{"issue":"12","key":"10.1016\/j.vaccine.2024.126663_bb0160","doi-asserted-by":"crossref","first-page":"3964","DOI":"10.1016\/j.celrep.2020.02.111","article-title":"Route of vaccine administration alters antigen trafficking but not innate or adaptive immunity","volume":"30","author":"Ols","year":"2020","journal-title":"Cell Rep"},{"issue":"1","key":"10.1016\/j.vaccine.2024.126663_bb0165","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12977-018-0443-0","article-title":"Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers","volume":"15","author":"Landais","year":"2018","journal-title":"Retrovirology"},{"issue":"10","key":"10.1016\/j.vaccine.2024.126663_bb0170","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1007\/s12033-019-00198-y","article-title":"Expression of breast Cancer-related epitopes targeting the IGF-1 receptor in chimeric human parvovirus B19 virus-like particles","volume":"61","author":"Salazar-Gonz\u00e1lez","year":"2019","journal-title":"Mol Biotechnol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24013458?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24013458?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T15:13:44Z","timestamp":1739200424000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24013458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":34,"alternative-id":["S0264410X24013458"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.126663","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and evaluation of a multi-epitope HIV-1 vaccine based on human parvovirus virus-like particles","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.126663","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"126663"}}